Oric Pharmaceuticals (ORIC) announced the appointment of Kevin Brodbeck to the newly established role of chief technical officer, or CTO. Brodbeck brings more than 25 years of experience leading technical operations, quality assurance, chemistry, manufacturing and controls and regulatory activities across a wide range of pharmaceutical products at all stages of development and commercialization. The creation of the CTO role and Brodbeck’s appointment reflect the impending advancement of ORIC’s clinical programs into late-stage development with the potential start of Phase 3 trials for ORIC-944 and enozertinib, or ORIC-114, in 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC:
- Oric Pharmaceuticals: Promising Future with Key Trials and Financial Stability Underpinning Buy Rating
- Oric Pharmaceuticals price target lowered to $19 from $22 at H.C. Wainwright
- Oric Pharmaceuticals Faces Potential Setbacks Amid Competitors’ Clinical Trials
- Oric Pharmaceuticals Focuses on Lead Clinical Programs
- Oric Pharmaceuticals reports Q2 EPS (47c), consensus (44c)